Sachdeva Geetanjali, D'Costa Jenice, Cho Jang E, Kachapati Kritika, Choudhry Vidita, Arya Suresh K
Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Med Virol. 2007 Feb;79(2):118-26. doi: 10.1002/jmv.20767.
Lentiviruses are unique in their ability to infect both dividing and non-dividing cells. This makes the vectors derived from them particularly useful for gene transfer into non-dividing cells, including stem cells. Lentiviral vectors are becoming the vectors of choice for si/shRNA delivery. The utility of the lentiviral vectors will be enhanced if additional elements of safety are built into their design. One safety concern is the generation of replication competent virus by recombination. We reasoned that HIV-1 and HIV-2 hybrid or chimeric lentiviral vectors will have added safety insurance in this regard. This is based on the premise that HIV-1 and HIV-2 are dissimilar enough in sequence to curtail recombination, yet similar enough to complement functionally. For hybrid vectors, we found that both HIV-1 and HIV-2 transfer vector RNAs could be packaged to equivalent titer by the HIV-1 packaging machinery. However, HIV-2 packaging machinery was unable to package HIV-1 transfer vector as well as it did HIV-2 transfer vector. This non-reciprocacity suggested that the requirement for HIV-2 vectors was more stringent and that for HIV-1 vectors more promiscuous. When the HIV-1 transfer vector was packaged with the chimeric packaging construct where the leader-gag region of HIV-2 was replaced with that of HIV-1 packaging construct, the titer of the vector went up. This suggests that at least some of the determinants of specificity for vector assembly reside in the leader-gag region. Incorporation of central polypurine tract (cPPT) and woodchuck post-transcriptional enhance element (WPRE) into the HIV-2 vectors had only modest effect on vector titer. Thus, chimeric lentiviral vectors with added safety features can be designed without compromising transduction efficiency.
慢病毒能够感染分裂细胞和非分裂细胞,这一特性使其独具特色。这使得源自慢病毒的载体在将基因导入非分裂细胞(包括干细胞)方面特别有用。慢病毒载体正成为用于递送小干扰RNA(si/shRNA)的首选载体。如果在慢病毒载体的设计中加入更多安全元件,其效用将得到增强。一个安全问题是通过重组产生具有复制能力的病毒。我们推断,在这方面,HIV-1和HIV-2杂交或嵌合慢病毒载体将增加安全保障。这是基于这样一个前提,即HIV-1和HIV-2在序列上差异足够大以减少重组,但在功能上又足够相似以相互补充。对于杂交载体,我们发现HIV-1和HIV-2转移载体RNA都可以被HIV-1包装机制包装到相同的滴度。然而,HIV-2包装机制不能像包装HIV-2转移载体那样有效地包装HIV-1转移载体。这种非对等性表明对HIV-2载体的要求更为严格,而对HIV-1载体的要求则更为宽松。当HIV-1转移载体与嵌合包装构建体一起包装时,其中HIV-2的前导- gag区域被HIV-1包装构建体的相应区域取代,载体的滴度提高了。这表明至少一些载体组装特异性的决定因素存在于前导- gag区域。将中央多嘌呤序列(cPPT)和土拨鼠转录后增强元件(WPRE)整合到HIV-2载体中对载体滴度的影响不大。因此,可以设计出具有额外安全特征的嵌合慢病毒载体,而不会损害转导效率。